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Abstract 25 
Ethical and technical difficulties inherent to studies in human tissues are impeding 26 
assessment of the dermal bioavailability of brominated flame retardants (BFRs). This is 27 
further complicated by increasing restrictions on the use of animals in toxicity testing, and the 28 
uncertainties associated with extrapolating data from animal studies to humans due to inter-29 
species variations. To overcome these difficulties, we evaluate 3D-human skin equivalents 30 
(3D-HSE) as a novel in vitro alternative to human and animal testing for assessment of 31 
dermal absorption of BFRs. The percutaneous penetration of hexabromocyclododecanes 32 
(HBCD) and tetrabromobisphenol-A (TBBP-A) through two commercially available 3D-HSE 33 
models was studied and compared to data obtained for human ex vivo skin according to a 34 
standard protocol. No statistically significant differences were observed between the results 35 
obtained using 3D-HSE and human ex vivo skin at two exposure levels. The absorbed dose 36 
was low (less than 7%) and was significantly correlated with log Kow of the tested BFR. 37 
Permeability coefficient values showed increasing dermal resistance  to  the  penetration  of  γ-38 
HBCD   >   β-HBCD   >   α-HBCD > TBBPA. The estimated long lag times (> 30 minutes) 39 
suggests that frequent hand washing may reduce human exposure to HBCDs and TBBPA via 40 
dermal contact.        41 
 42 
Keywords: Dermal absorption, Human skin equivalents, Human ex vivo skin, HBCDs, 43 
TBBPA, EPISKIN.    44 
 45 
46 
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Introduction 47 
Brominated flame retardants (BFRs) are a diverse group of chemicals widely used to prevent 48 
or reduce the flammability and combustibility of polymers and textiles. Among the major 49 
members of this group are Tetrabromobisphenol A (TBBP-A) and hexabromocyclododecane 50 
(HBCD) with estimated global production volumes of 170,000 and 16,700 tons, respectively 51 
(BSEF 2014). Since HBCD and ~20% of the produced TBBP-A are blended physically 52 
within, rather than bound chemically to polymeric materials; they migrate from products, 53 
following which their persistence and bioaccumulative character leads to contamination of 54 
the environment including humans (Harrad, et al. 2010). This is of concern owing to their 55 
potential toxicological risks including: endocrine disruption, neurodevelopmental and 56 
behavioral disorders, hepatotoxicity and possibly cancer (Darnerud 2008; Wikoff and 57 
Birnbaum 2011). Such evidence has contributed to several regulations (e.g. REACH) under 58 
different jurisdictions to control the production and use of these hazardous chemicals. 59 
Recently, HBCD was listed under Annex A of the Stockholm Convention on Persistent 60 
Organic Pollutants (POPs) (UNEP 2014).  61 
Substantial data exist on concentrations of different FRs in various environmental and human 62 
matrices (Covaci, et al. 2009; Law, et al. 2014; van der Veen and de Boer 2012). Current 63 
understanding is that non-occupational human exposure to BFRs occurs mainly via a 64 
combination of diet, ingestion of indoor dust, dermal contact with dust/consumer products, 65 
and inhalation of indoor air (Abdallah, et al. 2008a; Frederiksen, et al. 2009; Watkins, et al. 66 
2011). The exact contribution of these pathways varies substantially between chemicals, 67 
between individuals according to lifestyle, and is further complicated by international 68 
variations in FR use (Abdallah and Harrad 2009; Abdallah, et al. 2008a; Abdallah, et al. 69 
2008b).  70 
Currently, very little is known about dermal uptake as a route of human exposure to BFRs in 71 
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indoor dust or flame-retarded products. Watkins et al. reported a significant positive 72 
correlation between PBDE levels on hand wipes (presumably resulting from hand contact 73 
with contaminated dust or flame-retarded products) and PBDE levels in blood serum from 74 
American adults. While concentrations of PBDEs in indoor dust were strongly correlated 75 
with those in hand wipes, correlation could not be established directly between PBDE 76 
concentrations in indoor dust and their levels in serum (Watkins, et al. 2011). This opens up 77 
the possibility that FRs in dust may also be an indicator of another exposure pathway, such as 78 
direct dermal uptake of FRs present in treated goods (e.g. games consoles, remote controls, 79 
and fabrics). However, the absence of experimental data on human dermal absorption of 80 
various BFRs was recently highlighted as a major research gap hampering their accurate 81 
exposure assessment. Efforts to fill this gap are currently impeded by several difficulties 82 
including: ethical and technical issues inherent to studies involving human tissues, increasing 83 
restrictions on the use of laboratory animals in toxicological studies and the substantial 84 
uncertainties associated with extrapolating data from animal studies to humans due to inter-85 
species variation (e.g. skin barrier function, hair follicles, intercellular subcutaneous lipids 86 
…etc)  (Abdallah, et al. 2015a).  87 
To overcome these difficulties, this study will evaluate the application of in vitro 3D-human 88 
skin equivalents (3D-HSE) as an alternative method to animal and human testing for 89 
assessment of dermal uptake of HBCDs and TBBPA. 3D-HSE are commercially available, 90 
fully differentiated, multi-layered dermal tissues that closely mimic the original human skin 91 
histologically and physiologically (Schaefer-Korting, et al. 2008a). 3D-HSE consist mainly 92 
of primary human cells (e.g. keratinocytes and fibroblasts) obtained from healthy consenting 93 
donors, which are then cultured at the air-liquid interphase on a specially designed inert 94 
support that allows cell growth in a nutrient culture medium (Figure SI-1). While cells grown 95 
in 2D monolayers (e.g. Caco-2 cell models) cannot capture the relevant complexity of the in 96 
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vivo microenvironment as they lack a myriad of important signals, key regulators, and tissue 97 
phenotypes; cells growing in 3D tissue cultures have different cell surface receptor 98 
expression, proliferative capacity, extracellular matrix synthesis, cell density, and metabolic 99 
functions that resemble closely the original human tissue (Brohem, et al. 2011). 100 
Consequently, validated protocols using 3D-HSE models have been approved by the OECD 101 
(Organisation for Economic Co-operation and Development) and ECVAM (European Centre 102 
for Validation of Alternative Methods) for testing skin irritation, phototoxicity and corrosion 103 
by xenobiotic chemicals (Ackermann, et al. 2010; Buist, et al. 2010).  104 
While 3D-HSE have been successfully applied within the cosmetics and pharmaceutical 105 
sectors to study dermal uptake of various drugs (Ackermann, et al. 2010; Schaefer-Korting, et 106 
al. 2008a), this study of dermal uptake of BFRs, is the first application of 3D-HSE to better 107 
understanding of human dermal uptake of environmental contaminants. Our overall objective 108 
was to demonstrate the substantial potential of these models to transform how human dermal 109 
exposure to such contaminants is assessed. Nested within this, our specific aims were to: (a) 110 
develop and apply a standard protocol for assessment of percutaneous penetration of HBCDs 111 
and TBBPA using 2 commercially available 3D-HSE models (EPISKIN™ and EpiDerm™) 112 
according to the OECD guidelines; (b) compare the results of 3D-HSE models to those 113 
obtained from in vitro excised human skin (ex vivo skin); and (c) provide the first insights 114 
into the dermal bioavailability of our target BFRs in humans.  115 
 116 
Materials and Methods 117 
Experiments were performed along the principles of good laboratory practice and in 118 
compliance with the OECD guidelines for in vitro dermal absorption testing (OECD 2004). 119 
The handling instructions and performance characteristics of the tested 3D-HSE models were 120 
also taken into consideration. The study protocol received the required ethical approval (# 121 
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ERN_12-1502)  from  the  University  of  Birmingham’s  Medical,  Engineering  and  Mathematics  122 
Ethical Review Committee. 123 
 124 
Test matrices. 125 
The EpiDerm™ EPI-212-X human skin equivalent kit was purchased from MatTek 126 
Corporation (Ashland, MA).  The EPI-212-X tissue constructs are 0.64 cm2 human skin 127 
equivalents resembling the normal human epidermis histologically and physiologically 128 
(www.mattek.com). The kit includes maintenance medium (MM) - which is a proprietary 129 
DMEM (Dulbecco's Modified Eagle's Medium)-based medium - that allows acceptable 130 
differentiated morphology of the tissue for ~ 5 days upon receipt by end users.  131 
The   EPISKIN™   RHE/L/13   human   skin   equivalent   kit   was   purchased   from   SkinEthic  132 
Laboratories (Lyon, France). The RHE/L/13 tissue constructs are 1.07 cm2 supplied with 133 
enough MM to allow acceptable tissue differentiation (www.episkin.com). Upon receipt, the 134 
EPISKIN™  and  EpiDerm™ tissues were equilibrated overnight with their MM at 5% CO2 135 
and 37 ˚C before use in the permeation experiments. 136 
Fresh excised human upper breast skin was obtained via Caltag Medsystems Ltd. 137 
(Buckingham, UK) from 3 consented female adults (aged 36, 33 and 37 years) following 138 
plastic surgery. Selection criteria included: Caucasian, no stretchmarks, no scars and no hair.  139 
Full thickness skin without adipose tissue and an overall thickness of 550 ± 80 µm was used. 140 
Upon receipt, the ex vivo skin samples were equilibrated for 1 hour with 3 mL of DMEM-141 
based (Sigma-Aldrich, UK) culture medium (Table SI-1) at 5% CO2 and 37 ˚C before use in 142 
permeation experiments. 143 
 144 
Dosing Solutions 145 
 According to the OECD guidelines (OECD 2004), two different concentration levels of (I) 5 146 
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ng/µL  and  (II)  10  ng/µL  of  each  of  α-HBCD,  β-HBCD,  γ-HBCD and TBBP-A (Wellington 147 
Laboratories Inc., ON, Canada) were prepared in acetone. Based on the exposed surface area, 148 
a net dose of 500 ng/cm2 (~7.8 µM/cm2) and 1000 ng/cm2 (~15.6 µM/cm2) was applied to 149 
each of the investigated skin tissues using an appropriate volume (100 µL) of dosing 150 
solutions I and II, respectively. The applied doses fall within the range of potential human 151 
exposure to the studied BFRs via contact with indoor dust (Abdallah, et al. 2008a). Moreover, 152 
they allow for measurement of expected low percentages (up to 0.01%) of the applied dose in 153 
various compartments of the exposure model.      154 
To study the possible effect of the dosing vehicle on the percutaneous penetration of the 155 
tested chemicals, target BFRs were dissolved in 3 different dosing vehicles of: (A) acetone, 156 
(B) 30% acetone in water, and (C) 20% Tween 80 (Sigma-Aldrich, UK) in water at a 157 
concentration of 5 ng/µL. Preparation of the higher dosing level (i.e. 10 ng/µL) was not 158 
possible due to limited solubility of target BFRs in vehicles (B) and (C).  159 
 160 
Permeation assay protocol 161 
The permeation experiments were performed using the static set-up approach (Figure 1). Skin 162 
tissues were mounted in standard Franz-type permeation devices with stratum corneum 163 
facing up. Based on the recommendation of the 3D-HSE providers, the EpiDerm™ tissues 164 
were mounted in specifically designed MatTek™ permeation devices (MatTek Corporation, 165 
Ashland, MA),   the  EPISKIN™  tissues  were  mounted   in   special   inserts  constructed   for   this 166 
model (SkinEthic Laboratories, Lyon, France), while excised human skin tissues were 167 
mounted in standard glass Franz cells.  168 
All experiments were performed in triplicate. Following 30 minutes equilibration, the tested 169 
chemicals were applied onto the skin surface in the donor compartment. A DMEM-based 170 
culture medium (Table SI-1) was used as receptor fluid, maintained at 32 ± 1 °C and 171 
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magnetically stirred. To comply with the OECD guidelines, 5% bovine serum albumin (BSA) 172 
was added to the receptor fluid (Table SI-1) to enhance the solubility of target analytes, while 173 
the levels of test compounds in the donor solutions were chosen to ensure that the 174 
concentrations in the receptor fluid during the experiment did not exceed 10% of the 175 
saturation solubility.  176 
At fixed time points (0.25, 0.5, 0.75, 1, 2, 4, 6, 10, 12, 18, 20 and 24 h), aliquots of the 177 
receptor fluid (2 mL) were collected from the receptor compartment and immediately 178 
replaced with fresh fluid. After 24 hours, the entire receptor fluid was collected and the skin 179 
surface washed thoroughly with cotton buds impregnated in (1:1) hexane:ethyl acetate (5 180 
times). The tissues were removed from the permeation devices and both the donor and 181 
receptor compartments were washed separately (5 x 2 mL) with (1:1) hexane:ethyl acetate. 182 
All samples were stored at -20 ˚C until chemical analysis. 183 
 184 
Sample extraction and chemical analysis 185 
Each permeation assay generated five different types of samples comprising: receptor fluid at 186 
various time points, skin tissue, cotton buds (used to thoroughly wipe the skin surface), donor 187 
and receptor compartment washes. 188 
 The receptor fluid, skin tissue and cotton bud samples were extracted according to a 189 
previously reported QuEChERs-based method (Abdallah, et al. 2015b) (more details in the 190 
supplementary data section).  191 
The donor and receptor compartment washes were spiked with 30 ng of the 13C-labeled 192 
internal standard mixture prior to direct evaporation under a gentle stream of N2. Target 193 
analytes were reconstituted in 100 µL of methanol containing 100 pg/µL d18- α-HBCD used 194 
as recovery determination (syringe) standard for QA/QC purposes. 195 
Instrumental analysis was carried out using an LC-MS/MS system composed of a dual pump 196 
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Shimadzu LC-20AB Prominence liquid chromatograph equipped with SIL-20A autosampler, 197 
a DGU-20A3 vacuum degasser coupled to a Sciex API 2000 triple quadrupole mass 198 
spectrometer. Details of the multi-residue analytical methodology used for separation and 199 
quantification of the studied BFRs can be found elsewhere (Abdallah and Harrad 2011), with 200 
a brief description provided as supplementary data. 201 
 202 
Data analysis and statistical methods     203 
A quantitative description of test compound permeation through the skin barrier is obtained 204 
from Fick’s  first  law  of  diffusion as follows (Niedorf, et al. 2008): 205 
𝑱𝒔𝒔 =
𝜟𝒎
𝜟𝒕. 𝑨 =   
𝑫.𝑲. ∆𝑪
∆𝒙                                               (𝟏) 
Where Jss = steady-state flux [ng/cm2.h];;  Δm = permeated mass [ng];;  Δt = time interval [h]; D 206 
= diffusion coefficient [cm2/h]; K = partition coefficient; A = area [cm2];;  Δc = concentration 207 
difference [ng/cm3]; Δx: thickness of membrane [cm]. 208 
When using infinite-dose configurations, i.e. in which the donor concentration far exceeds the 209 
concentration in the receptor compartment (CD>>CA),   ΔC can be replaced by the known 210 
donor concentration, CD, and the permeated mass per time assumed constant. Therefore, the 211 
apparent permeation coefficient (Papp), which represents an independent measure of the 212 
membrane resistance against permeation of the examined substance, can be calculated as:    213 
𝑷𝒂𝒑𝒑 =   
𝑱𝒔𝒔
𝑪𝑫
                                      (𝟐) 
For each permeation experiment, cumulative amounts of the permeated compounds in the 214 
receptor fluid per unit area (ng/cm2) were plotted versus time (hours). Steady state conditions 215 
were indicated by a linear regression line (R2 ≥ 0.9), the slope of which represents the flux 216 
(Jss). Determination of the start and upper boundary of the linear range (i.e. steady state 217 
conditions) was achieved according to the method described by Niedorf et al. (Niedorf, et al. 218 
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2008) (a summary flow chart is provided in figure SI-2). 219 
Results are presented as the arithmetic mean of 3 replicates ± standard deviation (SD). 220 
Statistical analysis was performed using SPSS 13.0 software package. Differences in skin 221 
permeation were evaluated by the paired student t-test between 2 datasets. A Games-Howell 222 
test was used for analysis of variance (ANOVA) among several datasets with equal variances 223 
not assumed; p < 0.05 was regarded to indicate a statistically significant difference.   224 
 225 
QA/QC  226 
Several stages of QA/QC measurements were performed to check the performance of 227 
permeation  assay  protocol.  A  “field”  blank,  comprising  a  skin  tissue  exposed  to  solvents  only  228 
and treated as a sample, was performed with each sample batch (n= 9). None of the studied 229 
compounds were above the limit of detection (LOD) in the field blank samples. Good 230 
recoveries of the 13C-labeled internal standards (> 80%) were obtained indicating high 231 
efficiency of the extraction method (Table SI-3).  232 
Based on the guidelines of EPISKIN™ and EpiDerm™ models, the viability of the tissue was 233 
tested by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay using a 234 
standard kit purchased from each provider. Acceptable MTT results (i.e. Formazan 235 
concentration ≥ 1.5 mg/ml) were achieved following 24 hours of exposure. Both positive and 236 
negative control experiments were carried out alongside each sample batch. Positive controls 237 
involved the exposure of the test tissue to Triton-X-100 which showed ~ 100% permeation 238 
(n=5; 97 ± 4%), while negative controls showed 0% penetration of decabromodiphenyl 239 
ethane after 24 hours exposure. The integrity of the skin membrane was tested using the 240 
standard trans-epidermal electrical resistance (TEER) and methylene blue (BLUE) standard 241 
methods (Guth, et al. 2015). One excised human skin patch failed the membrane integrity 242 
test; hence its results were excluded from this study.   243 
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  244 
Results and Discussion       245 
Mass balance and absorbed fractions 246 
The efficiency of the experimental approach was investigated using a mass balance exercise. 247 
Results revealed good overall recoveries (>85%) for the target compounds using different 248 
permeation devices (Table 1). However, the use of specifically-designed permeation devices 249 
for the EPISKIN™ and EpiDerm™ models minimized the formation of air bubbles 250 
underneath the skin surface and reduced the handling-time and operator involvement during 251 
sampling of the receptor fluid at different time points.  252 
For simplicity, results of the permeation experiments were grouped under three major 253 
compartments: The directly absorbed dose (cumulative concentration in the receptor fluid 254 
over 24 h + receptor compartment rinse), the skin (concentration in the skin tissue after 24 h) 255 
and the unabsorbed dose (concentration in the skin surface wipes after 24 h + donor 256 
compartment rinse). Experimental results revealed higher permeation of all target compounds 257 
in the following order: EpiDerm™ >EPISKIN™ > Human ex vivo skin at the two 258 
concentration levels studied (Table 1 and Table SI-4). However, statistical analysis showed 259 
no significant differences (P > 0.05) among the levels of target analytes in the 3 major 260 
compartments of the examined tissues. Border line statistical significances (P = 0.053 and 261 
0.056) were observed between the results of human ex vivo skin and those of EpiDerm™  for  262 
β-HBCD   and   EPISKIN™   for   TBBPA,   respectively.   The   EpiDerm™  model   displayed   the  263 
largest permeation difference from human ex vivo skin with ~25% increase in the permeated 264 
dose  of  β-HBCD over 24 hours exposure.    265 
Previous studies comparing percutaneous permeation of chemicals through different in vitro 266 
models reported substantial inter-model differences. A 7-fold higher flux was observed for 11 267 
pesticides across in vitro rat skin compared to human skin (van Ravenzwaay and Leibold 268 
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2004). For triclosan, a 3-fold higher dermal absorption in rat compared to human skin was 269 
observed, while an 8-fold increase in the absorbed dose was reported for BDE-47 (Roper, et 270 
al. 2006). Mouse skin showed higher permeability to several chemicals, in vitro, than either 271 
rat, pig or human skin (Hughes, et al. 2001). A comparative study conducted in 2006 272 
according to OECD guidelines reported less penetration of testosterone in pig and bovine 273 
skin (0.07 and 0.13 % of applied dose) compared to human skin (0.32 %), while EPISKIN™ 274 
and EpiDerm™ models showed higher permeations (0.53 and 2.36, respectively) (Schafer-275 
Korting, et al. 2006). It is noteworthy that both 3D-HSE producers claim that their skin 276 
models were further developed since 2006 to improve the barrier function. Hence the 277 
EPISKIN™ and EpiDerm™ models  used  in  this  study  are  listed  under  the  “enhanced  barrier  278 
function”   category,   which is different from those used in the 2006 study. Another well-279 
designed study reported higher diffusion of radiolabeled bisphenol A (BPA) through pig ear 280 
skin (65%) compared to human skin (45%), although the difference was not statistically 281 
significant at the 95% confidence level (Zalko, et al. 2011).                282 
Investigation of the directly absorbed dose through the tested skin models showed a uniform 283 
pattern of increasing permeation in the following order: TBBP-A > α-HBCD > β-HBCD > γ-284 
HBCD (Figure 2). This is generally in line with the physicochemical properties of the tested 285 
compounds, where TBBP-A has a lower mass and higher water solubility than HBCDs 286 
(Table SI-6). Furthermore, a statistically significant correlation (P < 0.05) was observed 287 
between the 24 h cumulative absorbed dose and the log KOW (Table SI-6) of the studied BFRs 288 
in all the tested in vitro models. This highlights the influence of physicochemical properties 289 
on the human dermal bioavailability of a chemical. 290 
 291 
Dermal flux (Jss) and permeation coefficients (Papp) 292 
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A plot of the cumulative absorbed mass of each target compound (ng/cm2) against time 293 
(hours) was used to estimate the Jss (ng/cm2.h) for each target BFR and the Papp (cm/h) for the 294 
examined skin models (Table 2).  The steady state range of the curve was identified 295 
according to the method reported by Niedorf et al. (Niedorf, et al. 2008), with a minimum of 296 
5 data points in the linear range required to establish each curve (Figure SI-3, Table SI-5).  297 
Following the application of a test compound to the skin, it needs to partition into and diffuse 298 
through the skin before reaching the receptor fluid. This results in a lag-time, tlag, with non-299 
detectable flux. The tlag is represented by the time intercept (i.e. x-axis intercept) of the 300 
regression line over the steady-state region of the permeation curve (Figure SI-3). Hence, tlag 301 
can be calculated from equation 3: 302 
𝒕𝒍𝒂𝒈 =   
𝒃𝟎
𝑱𝒔𝒔
… . . …… . (𝟑) 
Where b0 refers to the y-axis intercept of the linear regression line and Jss is the slope. 303 
Steady state flux (Jss) provides quantitative description of a xenobiotic permeation through 304 
the dermal barrier. This is expressed as the rate (ng/ cm2. h ) by which the tested chemical 305 
traverses the skin tissue to reach the receptor fluid (Niedorf, et al. 2008). With γ-HBCD 306 
showing lowest percutaneous penetration and TBBPA the highest, Jss of the studied BFRs 307 
ranged from 0.8 ˗ 1.5 ng/ cm2. h, 0.9 ˗ 1.5 ng/ cm2. h and 0.7 ˗ 1.3 ng/ cm2. h for the 308 
EPISKIN™, EpiDerm™ and human ex vivo skin, respectively (Table 2). Interestingly, α-309 
HBCD showed a consistently higher flux across skin than γ-HBCD at the studied doses 310 
(Table 2). This indicates a higher dermal bioavailability of α-HBCD compared to the β- and 311 
γ- isomers. In addition to slower biotransformation rates (Abdallah, et al. 2014) and higher 312 
uptake from the gastrointestinal tract (Abdallah, et al. 2012), the greater dermal 313 
bioavailability of α-HBCD is likely a contributory factor in the dramatic shift of the HBCD 314 
isomeric profile from predominantly γ-HBCD in the commercial formulations and abiotic 315 
samples  to  a  predominance  of  α-HBCD in biota (Covaci, et al. 2006).     316 
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The estimated Papp values indicate more resistance of human ex vivo skin to the penetration of 317 
target BFRs than the EPISKIN™ and EpiDerm™ models. However, this difference was not 318 
statistically significant. In addition, both 3D-HSE models and human ex vivo skin displayed 319 
increasing resistance to the penetration of BFRs in the same order of γ-HBCD > β-HBCD > 320 
α-HBCD > TBBP-A.      321 
The lipophilic nature, low polarity and low water solubility of the studied BFRs are 322 
manifested by long lag times (> 30 minutes; Table 2), which suggests that frequent hand 323 
washing may reduce human exposure to HBCDs and TBBPA via dermal contact. This is 324 
generally in line with the results of Watkins et al. who found that adults washing their hands 325 
fewer than four times/day had, on average, 3.3 times more pentaBDE in their handwipes 326 
compared with those who washed their hands four or more times/day and concluded that 327 
frequent hand washing may decrease exposure to PBDEs via dermal contact (Watkins, et al. 328 
2011). 329 
   330 
Effect of dosing vehicle 331 
Several studies in the pharmaceutical and cosmetic sectors have highlighted the influence of 332 
dosing vehicle on the percutaneous penetration of chemicals. However, these experiments 333 
were exclusively based on aqueous solutions and topical emulsions (Schaefer-Korting, et al. 334 
2008b). Very little is known about the quantitative effects of organic-based vehicles on the 335 
dermal penetration of xenobiotics. In general, a vehicle may hydrate the stratum corneum 336 
(SC), extract critical barrier components out of the skin, or damage the skin because it is a 337 
strong acid or base. Removing SC lipids may increase percutaneous absorption of drugs. 338 
Many organic solvents (e.g. chloroform and methanol) are employed to delipidize the skin, 339 
which increases the permeability of hydrophilic - but not lipophilic – compounds (Chiang, et 340 
al. 2012).  341 
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Since BFRs are highly lipophilic compounds with very low water solubility (Table SI-6), the 342 
few studies on their dermal absorption used organic vehicles to dissolve the target analytes. 343 
Hughes et al. used tetrahydrofuran (THF) as a vehicle for BDE-209 (Hughes, et al. 2001), 344 
while Roper et al. used acetone for dissolving BDE-47 (Roper, et al. 2006). In the current 345 
study, acetone was selected as the major dosing vehicle. This was based on its ability to 346 
dissolve the test compounds at the desired levels and its minimal effect on skin barrier 347 
functions. Abrams et al. studied the effect of various organic solvents on the trans-epidermal 348 
water loss (TEWL) as an indicator of skin barrier. Both acetone and hexane showed no 349 
significantly different effects than water, while a mixture of chloroform : methanol (2:1) 350 
caused the greatest significant increase in TEWL (Abrams, et al. 1993).   351 
To further investigate the potential effect of the dosing vehicle on percutaneous penetration 352 
of BFRs, human ex vivo skin and the EPISKIN™ model were exposed to 500 ng/cm2 of 353 
target BFRs in each of :(A) acetone, (B) 30% acetone in water, and (C) 20% Tween 80 in 354 
water for 24 h. Results revealed higher levels of target compounds were absorbed from 355 
vehicle C, which was more evident for TBBP-A and α-HBCD compared to β- and γ-HBCDs 356 
(Figures 3 and SI-4). This is in agreement with the reported enhancement of the dermal 357 
absorption of testosterone in the presence of surfactants including miglyol and Tween 80 358 
(Schaefer-Korting, et al. 2008b).  359 
Although the differences in permeation of the studied BFRs from the tested vehicles lacked 360 
statistical significance, the enhanced permeation of TBBP-A and α-HBCD (Figure 3) in the 361 
presence of Tween 80 is potentially pertinent within the context of human exposure. This is 362 
owing to the presence of natural surface active agents in human skin surface film 363 
(sweat/sebum mixture) (Stefaniak, et al. 2010), which may influence the dermal absorption of 364 
these BFRs. Therefore, detailed study of the effect of human skin surface film on the dermal 365 
uptake of various BFRs appears warranted in the near future. In conclusion, the data 366 
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presented here demonstrate the validity of the 3D-HSE models for studying human dermal 367 
uptake of BFRs and related environmental contaminants.   368 
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Tables 493 
Table 1: Distribution of target BFRs (expressed as % of exposure dose) in different fractions 494 
of the in vitro diffusion system following 24 hour exposure to 500 ng/cm2 of α-, β-, γ-495 
HBCDs and TBBP-A in acetone. 496 
 α-HBCD β-HBCD γ-HBCD TBBP-A 
 EPISKIN™ 
Receptor fluid (24h) 5.81 ± 1.04 3.86 ± 0.78 3.42 ± 0.94 6.29 ± 0.65 
Receptor rinse 0.10 ± 0.02 0.07 ± 0.02 0.11 ± 0.02 0.41 ± 0.28 
Directly absorbed fraction 5.90 ± 1.06 3.94 ± 0.82 3.46 ± 0.96 6.70 ± 0.92 
Skin-Epidermis (Depot) 30.06 ± 2.42 27.18 ± 2.28 23.66 ± 3.16 24.18 ± 2.54 
Skin wash (unabsorbed) 44.34 ± 4.04 51.47 ± 3.72 56.82 ± 4.58 53.53 ± 3.46 
Donor rinse (unabsorbed) 5.13 ± 0.64 3.16 ± 0.82 2.38 ± 1.06 4.93 ± 2.08 
Unabsorbed dose 49.47 ± 4.68 54.63 ± 4.54 59.20 ± 5.64 58.46 ± 5.54 
Total Recovery 85.43 ± 8.16 85.75 ± 7.64 86.32 ± 9.76 89.34 ± 9.02 
 EpiDerm™ 
Receptor fluid (24h) 6.35 ± 0.92 4.02 ± 1.04 3.74 ± 0.82 6.44 ± 0.59 
Receptor rinse 0.11 ± 0.04 0.10 ± 0.08 0.09 ± 0.04 0.34 ± 0.16 
Directly absorbed fraction 6.46 ± 0.94 4.13 ± 1.12 3.82 ± 0.86 6.78 ± 0.74 
Skin-Epidermis (Depot) 28.19 ± 3.18 24.39 ± 2.22 21.02 ± 3.52 23.79 ± 2.42 
Skin wash (unabsorbed) 45.73 ± 4.02 53.91 ± 3.44 58.84 ± 4.38 55.04 ± 4.29 
Donor rinse (unabsorbed) 5.07 ± 0.62 2.39 ± 0.52 1.97 ± 0.74 4.11 ± 1.27 
Unabsorbed dose 50.80 ± 4.64 56.30 ± 3.96 60.81 ± 5.12 59.15 ± 5.56 
Total Recovery 85.45 ± 8.76 84.82 ± 7.30 85.65 ± 9.50 89.72 ± 8.72 
 Human ex vivo skin 
Receptor fluid (24h) 4.88 ± 1.44 3.21 ± 1.06 3.01 ± 1.02 5.37 ± 0.65 
Receptor rinse 0.07 ± 0.02 0.11 ± 0.02 0.06 ± 0.02 0.21 ± 0.28 
Directly absorbed fraction 4.95 ± 1.44 3.32 ± 1.06 3.07 ± 1.48 5.57 ± 0.92 
Skin-Epidermis (Depot) 30.59 ± 2.28 27.82 ± 2.38 24.16 ± 2.24 24.71 ± 2.96 
Skin wash (unabsorbed) 47.05 ± 4.44 51.19 ± 4.68 56.48 ± 3.28 56.53 ± 4.46 
Donor rinse (unabsorbed) 5.23 ± 1.48 3.37 ± 1.02 2.07 ± 0.66 3.83 ± 2.08 
Unabsorbed dose 52.28 ± 5.92 54.56 ± 5.70 58.55 ± 3.94 60.37 ± 6.54 
Total Recovery 87.82 ± 7.84 85.70 ± 6.28 85.78 ± 7.38 85.65 ± 10.42 
  497 
 498 
 499 
 500 
 501 
Page 23 of 26 
 
Table 2: Steady state flux, permeation coefficient and lag time values estimated for the target 502 
BFRs using different in vitro skin models.  503 
 
 Flux (Jss)  
(ng/cm2.h) 
Permeation coefficient (Papp) 
(cm/h) 
Lag time  
(h) 
EPISKIN™ 
α-HBCD 1.25 2.50 x 10-04 0.80 
β-HBCD 0.84 1.69 x 10-04 1.01 
γ-HBCD 0.78 1.56 x 10-04 1.21 
TBBPA 1.47 2.93 x 10-03 0.72 
EpiDerm™ 
α-HBCD 1.33 2.74 x 10-04 0.77 
β-HBCD 0.88 1.77 x 10-04 0.97 
γ-HBCD 0.85 1.72 x 10-04 1.13 
TBBPA 1.48 2.97 x 10-03 0.60 
Human ex vivo skin 
α-HBCD 1.08 2.16 x 10-04 0.85 
β-HBCD 0.74 1.47 x 10-04 1.17 
γ-HBCD 0.69 1.37 x 10-04 1.26 
TBBPA 1.29 2.58 x 10-03 0.79 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
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Figures 515 
Figure 1: General outline of the experimental protocol applied for percutaneous permeation 516 
experiments. 517 
 518 
 519 
 520 
 521 
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 524 
 525 
 526 
Step 1: Equilibriation of the culture with receptor fluid
Step 2: Application of the contaminant onto the stratum corneum
Step 3: receptor fluid is collected (and replaced) at fixed time points.
Step 4: At the end of exposure experiment  (up to 24 hours), the 
stratum corneum is washed thoroughly, all the receptor fluid is 
collected, the cell culture is recovered from the diffusion cell and all 
samples are stored at -80ºC until analysis.
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Figure 2: Cumulative dose absorbed into the receptor fluid following exposure of (a) human 527 
ex vivo skin, (b) EPISKIN™ and (c) EpiDerm™ to 1000 ng/cm2 of target BFRs over 24 h. 528 
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Figure 3: Cumulative permeation (ng/cm2) into the receptor fluid following exposure of 532 
EPISKIN™ model to 500 ng/cm2 of target BFRs in (A) acetone, (B) 30% acetone in water, 533 
and (C) 20% Tween 80 in water for 24 h. 534 
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